U.S. Semiconductors Stock News

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Sociedad Química y Minera de Chile fair value estimate is...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Pentair fair value estimate is US$104 Pentair's US$110 share...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...

Thinking about what to do with Corpay stock? You are not alone; it has been a hot topic ever since recent price swings caught the attention of both cautious investors and growth optimists. Over just the past week, Corpay saw its shares dip by 2.7%, and that slide stretches to a 10.0% drop for the last 30 days. Year-to-date, the stock is down 12.3%. These moves might have some people concerned, but to put things in perspective, Corpay has still returned a solid 70.9% over three years, along...

As major U.S. stock indexes experience declines, particularly in the tech sector, and energy stocks outperform due to rising crude futures, investors are keenly observing market fluctuations and valuations. In this environment, growth companies with strong insider ownership can be appealing as they often signal confidence from those closest to the business.

As the U.S. stock market experiences a mixed performance with tech shares declining and the energy sector outperforming, investors are exploring diverse opportunities to navigate these fluctuating conditions. Penny stocks, despite their somewhat outdated name, continue to attract attention due to their potential for significant returns when backed by solid financials. This article examines three penny stocks that stand out for their financial strength and potential for growth, offering...

Nu Skin Enterprises recently reported progress in operational efficiency, innovation, and international expansion, highlighted by growth in its Rhyz Manufacturing segment and anticipation for the AI-powered Prysm iO device. This operational momentum is fueling greater user interest, especially as product innovation and technology integrations shape future customer engagement. We’ll explore how the upcoming Prysm iO device supports Nu Skin Enterprises’ investment narrative and potential for...

Despite an already strong run, Alibaba Group Holding Limited ( NYSE:BABA ) shares have been powering on, with a gain of...

In September 2025, Aquestive Therapeutics announced that the FDA will not require an advisory committee meeting for its Anaphylm sublingual epinephrine film, clearing a smoother regulatory path toward a potential launch. This decision signals increased confidence in both the product's regulatory prospects and the potential for accelerated adoption of needle-free epinephrine treatments. We'll explore how this clear regulatory pathway for Anaphylm could reshape Aquestive Therapeutics'...

With a price-to-earnings (or "P/E") ratio of 12.1x Boyd Gaming Corporation ( NYSE:BYD ) may be sending bullish signals...

Steven Madden’s consensus analyst price target has recently risen from $28.12 to $30.00, reflecting a shift in analyst sentiment. This update suggests increased confidence in the company’s near-term outlook, partly because of faster inventory turnover and operational improvements. Stay tuned to discover how ongoing market developments may continue to influence the narrative for Steven Madden stock. What Wall Street Has Been Saying Steven Madden’s stock has drawn increased attention from Wall...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Porch Group’s consensus analyst price target has jumped significantly, rising from $14.00 to $19.75 in the latest update. Much of this optimism is driven by robust revenue growth forecasts, now climbing to 14.4% per annum. As sentiment shifts, it is essential to stay informed to understand where analysts see this evolving narrative heading next. What Wall Street Has Been Saying Analyst commentary on Porch Group has intensified following the company’s strong recent performance and updated...

JPMorgan Chase & Co. ( NYSE:JPM ) has announced that it will be increasing its dividend from last year's comparable...

Halozyme Therapeutics has recently seen its consensus analyst price target edge upward, moving only narrowly from $70.56 to $71.67. This modest increase comes as analysts weigh improved earnings projections against ongoing regulatory uncertainties. The result is a balanced shift in sentiment. Stay tuned to discover strategies for keeping pace with future updates to Halozyme's evolving investment narrative. What Wall Street Has Been Saying Analyst commentary on Halozyme Therapeutics reflects a...

It seems like plenty of investors are keeping a close eye on Vanguard Index Funds, specifically the Vanguard S&P 500 ETF (VOO), these days, and for good reason. With no specific headline grabbing the spotlight, the subtle shifts in VOO’s performance might leave you wondering if we are looking at the start of a new trend or just a pause in what has already been an impressive run. The real question is what, if anything, these recent moves signal about the ETF’s underlying value—and if there is...

The consensus analyst price target for Workday stock has held steady, shifting only marginally from $279.05 to $282.05. This minimal movement reflects a balance of optimism about the company's AI-driven initiatives, as well as persistent concerns around macroeconomic and competitive pressures. Stay tuned to discover how you can stay informed about these evolving dynamics and the future narrative surrounding Workday's stock. What Wall Street Has Been Saying Recent analyst commentary on Workday...

General Electric's stock narrative has recently seen a shift, with the consensus analyst price target moving only slightly higher from $297.93 to $302.33. This subtle adjustment reflects heightened optimism around GE Aerospace’s commercial engines and services, as robust demand continues to drive positive expectations. Stay tuned to discover how closely following analyst sentiment can help you stay ahead of changes in GE’s evolving story. What Wall Street Has Been Saying Recent commentary...

Comstock Inc. (NYSEAM:LODE) was recently added to the S&P Global BMI Index, an event recognized as influential for attracting institutional attention. This inclusion can raise the company’s visibility with investment funds that track major indices, potentially broadening Comstock’s shareholder base in the aftermath. We'll examine how Comstock's index admission might reshape its investment narrative and reinforce its presence among global institutional investors. The end of cancer? These 29...

The consensus analyst price target for Strata Critical Medical has risen sharply from $5.83 to $7.83, reflecting a new wave of optimism around the company's prospects. This boost follows Strata's major acquisition of Keystone Perfusion Services, which analysts view as a smart and strategic use of the company's cash reserves. Stay tuned to discover how you can stay informed as Strata's narrative continues to evolve with each strategic move. What Wall Street Has Been Saying Analyst commentary...